Human papillomaviruses and cancer in Uganda

In a case-control study in Uganda, we examined associations between different cancer sites or types in relation to antibodies against human papillomaviruses (HPV)-16, -18 and -45. For each cancer site or type, the control group comprised all other cancers excluding those known, or thought to be associated with HPV infection (cancers of the uterine cervix, penis and eye). Among controls the seroprevalence of antibodies was 11% (68/616) against HPV-16, 5% (29/605) against HPV-18 and 6% (35/605) against HPV-45. Antibodies against HPV-16 were significantly associated with only two cancers: uterine cervix [prevalence of antibodies 27% (51/191); odds ratio (OR) 2.0, 95% confidence interval (CI) 1.2–3.1, P=0.01] and penis [prevalence of antibodies 27% (4/15); OR 6.4, 95% CI 1.7–24.3, P=0.01]. For both cancers, the risk increased with increasing anti-HPV-16 antibody titre (Ptrend=0.01 for each). No cancer site or type was significantly associated with antibodies against HPV-18 and -45.

[1]  J. Doorbar,et al.  Human Papillomaviruses , 2006, Methods in Molecular Medicine.

[2]  W. Wright,et al.  Prospective Study of Antibody to Human Papilloma Virus type 16 and Risk of Cervical, Endometrial, and Ovarian Cancers (United States) , 2001, Cancer Causes & Control.

[3]  V. Beral,et al.  Risk factors for Kaposi's sarcoma: A case‐control study of HIV‐seronegative people in Uganda , 2003, International journal of cancer.

[4]  John Ziegler,et al.  The sero‐epidemiology of Kaposi's sarcoma‐associated herpesvirus (KSHV/HHV‐8) in adults with cancer in Uganda , 2003, International journal of cancer.

[5]  V. Beral,et al.  The epidemiology of conjunctival squamous cell carcinoma in Uganda , 2002, British Journal of Cancer.

[6]  M. Plummer,et al.  Prevalence and determinants of human papillomavirus genital infection in men , 2002, British Journal of Cancer.

[7]  P. Coursaget,et al.  Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus‐like particles in colombian women with invasive cervical cancer , 2002, International journal of cancer.

[8]  P. Coursaget,et al.  Prevalence of Anti-Human Papillomavirus Type 16, 18, 31, and 58 Virus-Like Particles in Women in the General Population and in Prostitutes , 2001, Journal of Clinical Microbiology.

[9]  M. Hagensee,et al.  Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients , 2001, International journal of STD & AIDS.

[10]  V. Beral,et al.  A case‐control study of human immunodeficiency virus infection and cancer in adults and children residing in Kampala, Uganda , 2001, International journal of cancer.

[11]  P. Coursaget,et al.  Gene Transfer Using Recombinant Rabbit Hemorrhagic Disease Virus Capsids with Genetically Modified DNA Encapsidation Capacity by Addition of Packaging Sequences from the L1 or L2 Protein of Human Papillomavirus Type 16 , 2000, Journal of Virology.

[12]  H. Adami,et al.  Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study , 2000, The Lancet.

[13]  N. Kiviat,et al.  Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. , 2000, The Journal of infectious diseases.

[14]  A. Teyssié,et al.  Human papillomavirus (HPV) DNA in penile carcinomas in Argentina: Analysis of primary tumors and lymph nodes , 2000, Journal of medical virology.

[15]  D. Parkin,et al.  Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997 , 2000, British Journal of Cancer.

[16]  D. Parkin,et al.  AIDS-related cancers in Africa: maturation of the epidemic in Uganda. , 1999, AIDS.

[17]  K. Shah,et al.  Use of a hybrid capture assay of self-collected vaginal swabs in rural Uganda for detection of human papillomavirus. , 1999, The Journal of infectious diseases.

[18]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[19]  J. Dillner,et al.  Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. , 1999, The Journal of general virology.

[20]  P. Coursaget,et al.  Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. , 1999, The Journal of general virology.

[21]  M. Sapp,et al.  Prospective study on cervical neoplasia IV. Presence of HPV antibodies , 1999, International journal of cancer.

[22]  P. Coursaget,et al.  The L1 Major Capsid Protein of Human Papillomavirus Type 16 Variants Affects Yield of Virus-Like Particles Produced in an Insect Cell Expression System , 1998, Journal of Clinical Microbiology.

[23]  V. Beral,et al.  Risk factors for Kaposi's sarcoma in HIV‐positive subjects in Uganda , 1997, AIDS.

[24]  D. Lowy,et al.  Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. , 1997, The Journal of infectious diseases.

[25]  T. Bjørge,et al.  Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. , 1997, Journal of the National Cancer Institute.

[26]  C. Meijer,et al.  Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. , 1997, Journal of the National Cancer Institute.

[27]  K. Shah,et al.  Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[28]  N. Kiviat,et al.  The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. , 1996, The Journal of infectious diseases.

[29]  M. Lehtinen,et al.  Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. , 1996, The Journal of infectious diseases.

[30]  R. Peto,et al.  Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study , 1996, BMJ.

[31]  C. Boshoff,et al.  Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group. , 1996, Archives of internal medicine.

[32]  S. Dawsey,et al.  Serum antibodies to HPV 16 virus-like particles are not associated with penile cancer in Chinese males. , 1996, Viral immunology.

[33]  David R. Scott,et al.  Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. , 1995, The Journal of infectious diseases.

[34]  V. Moreno,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[35]  P. Coursaget,et al.  Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV 16 L1 capsids produced by recombinant baculovirus , 1995, Journal of clinical microbiology.

[36]  D. Lowy,et al.  A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. , 1994, Journal of the National Cancer Institute.

[37]  F. Buonaguro,et al.  Human papillomavirus (hpv) DNA in penile carcinomas and in two cell lines from high‐incidence areas for genital cancers in Africa , 1992, International journal of cancer.

[38]  Kyalwazi Sk.  Carcinoma of the penis. A review of 153 patients admitted to Mulago Hospital, Kampala, Uganda. , 1966 .

[39]  S. Kyalwazi.  Carcinoma of the penis. A review of 153 patients admitted to Mulago Hospital, Kampala, Uganda. , 1966, East African medical journal.

[40]  M. Paul.  Carcinoma of the Penis , 1952, Postgraduate medical journal.